These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25777185)

  • 41. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center.
    Gathe J
    Curr Med Res Opin; 2008 Mar; 24(3):769-73. PubMed ID: 18234149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
    Latini A; Fabbiani M; Borghi V; Sterrantino G; Giannetti A; Lorenzini P; Loiacono L; Ammassari A; Bellagamba R; Colafigli M; D'Ettorre G; Di Giambenedetto S; Antinori A; Zaccarelli M
    BMC Infect Dis; 2016 Aug; 16(1):401. PubMed ID: 27515949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
    Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J; Heera J; Mayer H
    HIV Clin Trials; 2010; 11(3):125-32. PubMed ID: 20736149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
    Tashima KT; Mollan KR; Na L; Gandhi RT; Klingman KL; Fichtenbaum CJ; Andrade A; Johnson VA; Eron JJ; Smeaton L; Haubrich RH
    HIV Clin Trials; 2015 Aug; 16(4):147-56. PubMed ID: 26212575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
    Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu A; Frank I; Ho K; Santana J; Stekler JD; McCauley M; Mayer KH
    J Infect Dis; 2017 Jan; 215(2):238-246. PubMed ID: 27811319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
    Tiraboschi JM; Niubo J; Curto J; Podzamczer D
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):606-9. PubMed ID: 20706127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
    Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Siegel M; Manabe YC; Frank I; Ho K; Santana J; Stekler JD; Swaminathan S; McCauley M; Hodder S; Mayer KH
    Ann Intern Med; 2017 Sep; 167(6):384-393. PubMed ID: 28828489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
    Ahmed N; Okoli C; Ainsworth J
    Int J STD AIDS; 2016 Mar; 27(4):321-2. PubMed ID: 25969439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
    Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
    Corrigan B; Mukui I; Mulenga L; Mthethwa N; Letsie M; Bruno S; Rakhmanina N
    Pediatr Infect Dis J; 2018 Jul; 37(7):669-672. PubMed ID: 29140932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.
    Chan ES; Landay AL; Brown TT; Ribaudo HJ; Mirmonsef P; Ofotokun I; Weitzmann MN; Martinson J; Klingman KL; Eron JJ; Fichtenbaum CJ; Plants J; Taiwo BO
    AIDS; 2016 Aug; 30(13):2091-7. PubMed ID: 27281061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
    J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
    McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.
    Pichenot M; Deuffic-Burban S; Cuzin L; Yazdanpanah Y
    HIV Med; 2012 Mar; 13(3):148-55. PubMed ID: 22107456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.